Brokerages expect Seres Therapeutics Inc (NASDAQ:MCRB) to report $10.29 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Seres Therapeutics’ earnings, with the lowest sales estimate coming in at $9.26 million and the highest estimate coming in at $11.90 million. Seres Therapeutics posted sales of $4.61 million in the same quarter last year, which suggests a positive year over year growth rate of 123.2%. The business is scheduled to report its next earnings report on Thursday, August 1st.
On average, analysts expect that Seres Therapeutics will report full year sales of $30.87 million for the current fiscal year, with estimates ranging from $22.32 million to $35.20 million. For the next fiscal year, analysts expect that the business will post sales of $39.68 million, with estimates ranging from $18.70 million to $56.50 million. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that that provide coverage for Seres Therapeutics.
Seres Therapeutics (NASDAQ:MCRB) last released its quarterly earnings results on Thursday, May 2nd. The biotechnology company reported ($0.55) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by ($0.12). The firm had revenue of $7.32 million for the quarter, compared to analysts’ expectations of $8.61 million. Seres Therapeutics had a negative net margin of 301.60% and a negative return on equity of 1,583.95%.
In related news, Director Noubar Afeyan acquired 8,888,888 shares of the firm’s stock in a transaction that occurred on Tuesday, June 18th. The stock was purchased at an average cost of $2.25 per share, with a total value of $19,999,998.00. Following the transaction, the director now directly owns 15,141 shares of the company’s stock, valued at approximately $34,067.25. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 37.00% of the company’s stock.
Institutional investors have recently made changes to their positions in the stock. Marshall Wace LLP acquired a new stake in Seres Therapeutics during the 1st quarter valued at approximately $842,000. ARK Investment Management LLC grew its stake in Seres Therapeutics by 28.4% during the 1st quarter. ARK Investment Management LLC now owns 5,287,713 shares of the biotechnology company’s stock valued at $36,327,000 after purchasing an additional 1,168,234 shares in the last quarter. DekaBank Deutsche Girozentrale grew its stake in Seres Therapeutics by 21.5% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 19,800 shares of the biotechnology company’s stock valued at $168,000 after purchasing an additional 3,500 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. acquired a new stake in Seres Therapeutics during the 1st quarter valued at approximately $5,504,000. Finally, Alpine Woods Capital Investors LLC acquired a new stake in Seres Therapeutics during the 1st quarter valued at approximately $412,000. 82.03% of the stock is owned by hedge funds and other institutional investors.
MCRB stock opened at $3.22 on Friday. The stock has a market capitalization of $118.37 million, a price-to-earnings ratio of -1.33 and a beta of 2.20. The firm’s 50-day moving average price is $3.47. Seres Therapeutics has a one year low of $2.02 and a one year high of $9.35.
About Seres Therapeutics
Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. The company's advanced program is the SER-109, which is in Phase III clinical development for reducing recurrent clostridium difficile infection (CDI).
Recommended Story: How to identify percentage decliners
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.